News
Resolve Therapeutics receives FDA approval to initiate Phase 2 clinical trial of RSLV-132 in long covid patients
Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that the US Food and Drug Administration has approved a New Investigational Drug application for RSLV-132 to initiate a phase 2 clinical trial in patients with long covid. It is estimated that up to 30% of patients
Read More
Zeotap launches Google Customer Match integration to drive addressability in a post-cookie world
Zeotap, the leading Customer Data Platform, has launched a new integration with Google Customer Match, enabling marketers to leverage their first-party data to engage audiences at scale across Google Search, Shopping, Gmail, YouTube and Display. In doing so, the new integration provides an important solution to addressability when third-party cookies
Read More
iCAD’s ProFound AI for Digital Breast Tomosynthesis Version 3.0 Receives CE Mark Approval
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ProFound AI® Version 3.0 for Digital Breast Tomosynthesis (DBT) received CE Mark approval. Compared to previous software versions, the latest generation of ProFound AI offers up to a 10% improvement in
Read More
CanCell Therapeutics partners with Ovizio to improve monitoring of CAR-T cell production
Ovizio Imaging Systems, a manufacturer of cell analyzers for advanced monitoring in the bioprocessing market, and CanCell Therapeutics, an early-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that they will enter into a collaboration to further improve the monitoring of CAR-T cell-therapy manufacturing. The partnership
Read More
Phase Four raises $26m led by New Science Ventures
Phase Four, the creator of the radio-frequency thruster for satellite propulsion, announced today that it has closed a Series B investment round of $26 million. The round was led by New Science Ventures LLC ("NSV"), a leading venture capital firm focused on building companies that leverage breakthrough science to create
Read More
Zeotap launches Predictive Audiences to empower marketers with machine learning
Zeotap the leading Customer Data Platform, has today announced the launch of Predictive Audiences as part of its award-winning Customer Intelligence Platform (CIP). Designed to help marketing users increase the impact of their campaigns, it enables the creation and application of machine-learned predictive segments in just a few clicks. Predictive
Read More
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal
Read More
Zeotap builds momentum as marketing industry shifts away from cookies
Zeotap, the Customer Intelligence Platform (CIP), has reported 126% ARR growth in 2020 among its latest milestones in growth. Building momentum from its $60.5 million Series C fundraising round last year, the company is capitalizing on the marketing industry’s move to better engage first-party data in the face of the
Read More
Achronix now shipping industry’s highest performance Speedster7t FPGA devices
Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, today announced that it has begun shipping its 7nm Speedster®7t AC7t1500 FPGAs to customers ahead of schedule. The Speedster7t family is purpose-built for high bandwidth workloads in a broad range of applications including AI/ML, 5G infrastructure, networking,
Read More
ABL Space raises $170m growth equity round led by T. Rowe Price funds
ABL Space Systems has closed a Series B investment round of $170 million at a valuation of $1.3 billion. The round was led by funds and accounts advised by T. Rowe Price Associates, Inc. Participation in the round included existing ABL investors and new investments by Fidelity Management & Research
Read More
Ventyx Biosciences doses first subject in a Phase 1 Trial of VTX-958, a selective allosteric TYK2 Inhibitor for Autoimmune Diseases
Ventyx Biosciences, Inc. a clinical-stage biotechnology company developing oral, small molecule therapeutics for autoimmune disease, today announced the dosing of the first subject in a Phase 1 clinical trial of VTX-958, a novel and selective allosteric TYK2 inhibitor. In non-clinical studies, VTX-958 has shown potential to treat autoimmune diseases by
Read More
New Science Ventures Portfolio Company Ventyx Biosciences Raises $114 Million
New Science Ventures LLC (“NSV”), a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value, announces that its portfolio company Ventyx Biosciences raised $114 million from blue-chip investors to advance a diverse pipeline of immunology programs. Ventyx Biosciences combines assets from three formerly
Read More